Media Releases

Find out about our recent activities

Click on the media releases below to learn more about recent InSphero company news, events, and achievements.

18.10.2017 - InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC

New 3D InSight™ Human Liver Fibrosis Model represents a powerful tool for screening efficacy and safety of anti-fibrotic drugs in vitro. PDF Version

Schlieren, Switzerland -  Oct 18, 2017  IInSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data characterizing and demonstrating the utility of its new 3D InSight™ Human Liver Fibrosis Model for screening efficacy of anti-fibrotic drugs.  The findings will be presented at oral and poster presentations this Friday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) Conference in Washington, DC. 

Anti-fibrotic therapies aim to inhibit activation of hepatic stellate cell (HSCs), thereby preventing excessive accumulation of extracellular matrix (ECM) proteins, such as collagen, which can lead to cirrhosis and liver failure.  The InSphero 3D InSight™ Human Liver Fibrosis Model is unique in that it contains all liver cell types necessary to mimic fibrosis in vitro in a high throughput, screening-compatible platform.   

InSphero Chief Scientific Officer Dr. Patrick Guye says, “Our 3D human fibrosis model is composed of primary human liver cells, including HSCs, hepatocytes, Kupffer cells, and liver endothelial cells, all of which are required to accurately reflect the clinical fibrotic disease state in a cell culture model. Treatment of the model with TGF-b1, a known inducer of HSC activation, was shown to trigger strong induction of pro-fibrotic gene expression and ECM protein accumulation in the microtissue, resulting in collagen deposition and diminished hepatocyte function, both hallmarks of liver fibrosis. Even more promising, we were clearly able to demonstrate successful inhibition of disease progression on a phenotypic and transcriptional level using drugs known to interfere with pro-fibrotic signalling pathways.” 

Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder, notes, “These findings support the power of our model to help drug discovery groups meet the demand for safer, more effective anti-fibrotic drugs. The initial feedback from beta testers within major pharmaceutical groups with fibrosis programs has been overwhelmingly positive.  Not only does the model overcome the lack of cellular complexity of current in vitro models, but being based on our pharma-validated Human Liver Microtissue platform, it can deliver valuable data on both the efficacy and safety of drug candidates, without the use of animal models.” 

AASLD Presentation Details
Friday, October 20: 12:00 - 1:30 PM
Abstract #385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
Poster presented by Dr. Radina Kostadinova, InSphero AG

For more information about InSphero, visit www.insphero.com.

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and InSphero Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology. All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Images

InSphero fibrosis model AASLD        Logo ohne Tagline ISGreen RGB

The 3D InSight™ Human Liver Fibrosis Model is a powerful in vitro tool used by pharmaceutical drug discovery groups to test the ability of novel anti-fibrotic drugs to prevent induced accumulation of collagen protein (green staining) within microtissues derived from primary human liver cells (blue DNA stain). 

29.06.2017 - Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury

Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury

Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds. PDF Version

Schlieren, Switzerland -  June 29, 2017  In the most comprehensive evaluation of 3D spheroid hepatic cultures conducted to date, a publication co-authored by lead toxicologists and drug safety experts at AstraZeneca and Genentech revealed InSphero 3D InSight™ Human Liver Microtissues to be a more sensitive and highly specific in vitro model for predicting drug-induced liver injury (DILI) compared to 2D models. The study entitled, “Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury,” was published online Tuesday, June 13 in the journal Archives of Toxicology. Dr. William Proctor, Head of Investigative Toxicology at Genentech, and Alison Foster, Senior Scientist in the Drug Safety and Metabolism group at AstraZeneca, were co-first authors on the publication.

2D PHH assays have been the “gold-standard” model used for DILI testing, yet DILI still remains one of the leading sources for drug attrition, black box warnings, and post-market withdrawal of drugs. Thus, there is a growing need for better predictive tools to assess liver injury earlier in the drug development process. The authors note in the paper that, “3D models have shown promise in small sets of DILI compounds, but a more comprehensive retrospective study of DILI positive and negative drugs to test the predictive power of 3D models head to head with 2D PHH assays had not been performed.”

The study determined that regardless of the threshold used, “Human Liver Microtissues demonstrated increased sensitivity in identifying known hepatotoxicants versus PHH, while specificity was consistent across both assays.” Microtissues also, “outperformed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules.” Furthermore, the authors found that 3D microtissues displayed sufficient structural and functional characteristics to warrant exploratory studies to see if novel biomarkers used in the clinic could also be detected in vitro. Findings revealed that despite each microtissue consisting of ~1000 cells, the mechanistic and exploratory hepatotoxicity biomarkers miR-122, HMGB1, and α-GST could be detected in the culture supernatants, demonstrating that, “3D liver microtissues have the potential to recapitulate in vivo findings in vitro.”

“This landmark study provides convincing, independent evidence that InSphero liver microtissues can help identify hepatotoxic drugs with greater sensitivity without sacrificing specificity, says InSphero Chief Executive Officer and Co-founder Dr. Jan Lichtenberg. “Having two of the world’s leading pharmaceutical companies collaborate to produce this thorough validation further confirms that our 3D models not only better reflect in vivo biology, but also deliver the reproducibility and scalability required to meet the early stage screening demands of large pharma. Our assay-ready 3D InSight™ models offer a cost-effective, turnkey solution that gives toxicologists greater confidence when characterizing risk in lead compound sets.”

3D InSight™ Human Liver Microtissues are a standardized primary human liver model developed by InSphero that display enhanced liver phenotype, metabolic activity, and stability over 28 days in culture, enabling long-term drug exposure studies not attainable with 2D hepatic models.

For more information about InSphero 3D InSight™ Islet Microtissues, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and InSphero Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Images

Liver Microtissue        Logo ohne Tagline ISGreen RGB

InSphero 3D InSight™ Liver Microtissues help drug discovery and development groups predict drug-induced liver injury (DILI) with greater confidence, providing more relevant and reliable 3-dimensional cell based models for in vitro drug safety testing.

19.06.2017 - ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening

ADA Presentations Highlight Superior Functionality of InSphero Standardized Islet Microtissues for Diabetes Drug Screening

ETH Zurich researchers present single-islet study using novel microfluidic setup to display in vivo-like temporal insulin response to high glucose. PDF Version

Schlieren, Switzerland -  June 19, 2017  InSphero AG highlighted unique advantages of its physiologically relevant 3D InSight™ Islet Microtissue Platform to drive more efficient development of anti-diabetic drugs at the American Diabetes Association 77th Scientific Sessions in San Diego, CA. Also, a pioneering study describing a microfluidic single islet perifusion platform, developed by researchers at the ETH Zurich, was presented during open and moderated poster sessions held during the conference.

Dr. Burcak Yesildag, islet product manager at InSphero and presenter of the study at ADA says, “Loss of first phase, reduction in the second phase and impairment of the oscillatory pattern of insulin secretion are characteristic features of type 2 diabetes. Therefore, study of dynamic insulin release with in vitro perifusion assays is a crucial component of pancreatic islet research. However, inherent heterogeneity in islet size and composition necessitates pooling of multiple islets for each experimental condition, which entails inefficient use of donor material and decreased experimental resolution due to uncoordinated inter-islet function.”

InSphero 3D InSight™ Islet Microtissues - uniform in size, cellular composition and function – were combined with a novel microfluidic system engineered by Dr. Andreas Hierlemann’s research group at the Swiss Federal Institute of Technology (ETH). The microfluidic system facilitates rapid glucose switches and short sampling intervals, making it possible to study dynamic insulin secretion at the single-islet level in vitro.

Says Yesildag, “ETH observed an organotypic biphasic and pulsatile secretion of insulin from our islet microtissues which was physiologically modulated by various insulin secretagogues. The results very closely mirrored the magnitude and frequency of the response seen in humans. This collaboration provides further evidence that the in vivo-like functionality of our islet model makes it a powerful new tool for islet researchers to help accelerate anti-diabetic drug development.”

3D InSight™ Islet Microtissues are a standardized primary islet model developed by InSphero that display organotypic function with an average 13-fold increase in glucose-stimulated insulin secretion (GSIS) for at least 28 days in culture.

For more information about InSphero 3D InSight™ Islet Microtissues, visit www.insphero.com or watch the video.

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Images

Islet no background          Logo ohne Tagline ISGreen RGB

InSphero 3D InSight™ Islet Microtissues help drug discovery and development groups identify more effective drugs for diabetes by providing more relevant and reliable 3-dimensional cell based models for in vitro efficacy testing.

18.04.2017 - NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

NIH/NCATS and InSphero Host Inaugural 3D Tumor Model Standards Working Group at AACR 2017

Establishing standards for next-generation tumor models to benefit drug discovery and broader research community primary objective of new group. PDF Vesion

Schlieren, Switzerland - April 18, 2017

The inaugural meeting of the 3D Standards Working Group was held during the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC, on Saturday, April 1.  Organized and hosted by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, and InSphero AG, the meeting drew representatives from academic institutions, pharmaceutical and life sciences industries, as well as government agencies, to discuss the use of 3D cancer models within drug discovery campaigns, and review biological and technical requirements needed for the next generation of high-throughput screening-compatible (HTS) models.

"There is a growing need for in vitro 3D tumor models that mimic in vivo tumor physiology for more efficient cancer drug discovery,” says InSphero Chief Scientific Officer Dr. Patrick Guye. “We sought to bring together key opinion leaders in academia, industry and government to develop guidelines that we believe are critical to establish 3D tumor models as a highly predictive platform for therapeutic drug development assays.” The group plans to publish its findings and recommendations for developing and using 3D tumor models for drug development, with the intent to make the best consensus information available to the broader research community.

“We made tremendous progress during this kickoff meeting,” says Dr. Madhu Lal Nag, Head of the Trans NIH RNAi Facility at NCATS. “We not only discussed where we stand today, with regard to developing advanced 3D models that capture the complexity of the tumor microenvironment, but also delved into needs for standardized nomenclature, benchmarking, improved model predictivity, and multiparametric readouts.” Going forward, the group plans to meet quarterly by teleconference and in person during future conferences, such as AACR, which most members of the working group attend.

For more information about NCATS, visit https://ncats.nih.gov.

For more information about InSphero, visit www.insphero.com

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero sets the standard for in vitro testing of novel drugs in the pharmaceutical and biotechnology industry with comprehensive solutions that provide greater confidence in decision making. Its robust and highly physiologically relevant suite of 3D InSight™ Microtissues and Services are used by major pharmaceutical companies worldwide to increase efficiency in drug discovery and safety testing. InSphero patent-pending technologies and methods enable large-scale, reproducible production of scaffold-free 3D microtissues driven solely by cellular self-assembly. The company specializes in delivering assay-ready and custom 3D models derived from liver, pancreas, and tumor tissues, to provide unrivalled biological insight into liver toxicology, metabolic diseases (e.g., diabetes and liver diseases), and oncology (with a focus on immuno-oncology). All InSphero microtissues are thoroughly validated to ensure the highest quality, certified for use in a variety of assays, and shipped globally to customers in a patented, easy-to-use spheroid-optimized platform, ready for research. Field application scientists and research staff with expertise in working with 3D models help ensure efficient integration and onsite training as needed. For customers who prefer an outsourcing strategy with fast turnaround, InSphero also offers contract research services utilizing their 3D microtissue models.

InSphero 3D InSight™ solutions drive significant findings in peer-reviewed journals, through collaborative industry initiatives such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn.

 

Image

insphero logo

 

03.04.2017 - Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies

Novel 3D Cell-based Assays Accelerate Discovery for Immuno-oncology/CAR-T Therapies 

InSphero presents latest data demonstrating immune cell interaction with 3D tumor models for in vitro efficacy testing of oncology drugs and immunotherapies at AACR.  PDF Version

Schlieren, Switzerland - April 03, 2017 –  InSphero AG highlighted the unique advantages of its physiologically relevant 3D InSight™ Microtissue Platform to drive more efficient development of anti-cancer drugs and immuno-oncology (I-O) approaches at the American Association of Cancer Research (AACR) Annual Meeting in Washington, DC. The presentations included data generated in collaboration with academic, government, and industry partners.

“Our presentations at this year’s AACR meeting display not only the variety and complexity of tumor models we can produce through our Custom Tumor Microtissue Development Service, but also the breadth of applications for which they can be used throughout the drug development pipeline,“ said Dr. Jens Kelm, InSphero Chief Technology Officer and Co-founder. “These range from early discovery screens in cell-line based 3D microtissue models in 384-well format to more complex pre-clinical development and validation studies, using co-cultures of fibroblasts with cancer cell lines or patient-derived xenograft (PDX) samples.”

In addition, InSphero presented data demonstrating the infiltration of activated immune cells, such as peripheral blood mononuclear cells (PBMCs), into tumor-stromal co-culture models. “Recent successes in I-O therapies for blood-borne cancers has triggered the race in pharma for similar strategies targeting solid tumors,” Dr. Kelm said. “Our technology provides the first turnkey 3D platform for mimicking complex solid tumor environments in vitro. It is designed specifically for the development and optimization of CAR-T, CAR-NK, or immunomodulatory based I-O strategies.” InSphero scientists recently showed that activated PBMCs can penetrate tumor-stromal microtissues and specifically kill tumor cells. The findings were published in a collaborative study with Roche Pharmaceutical and ETH Zurich in the January 2017 issue of the journal Cancer Immunology, Immunotherapy.

“We have presented work done in collaboration with the University of Zurich as well, where we’ve created microtissues directly from patient tumor biopsy material,” Dr. Kelm said. “This approach holds potential for in vitro testing in the clinical phase to help identify a personalized treatment plan using drugs most effective against the biopsied material cultured in 3D.”

In addition to custom model development, InSphero offers 3D InSight™ Oncology Services, including single or combinatorial drug testing, tumor relapse, and antibody penetration assays, all of which can be conducted on customized tumor microtissues, or on established tumor-stromal co-culture models. 

InSphero AACR Poster Presentations

Wednesday, April 5 (8 AM – 12 PM)
Poster 5781/17 (Section 38): Establishment of a 3D ex vivo assay as a preclinical drug testing platform for personalized cancer therapy. Presented by Dr. Sumeer Dhar, InSphero AG (collaboration with University of Zurich).

Wednesday, April 5 (8 AM – 12 PM)
5780/16 (Section 38): 3D ex vivo assay platform using primary lung cancer cells in malignant pleural effusions as predictors for clinical outcome of personalized chemotherapy.Presented by Cheng-guang Wu, University of Zurich (collaboration with InSphero AG).

In-booth Poster Presentations

Booth 1029 (Sunday 12 PM – Wednesday 12 PM, during exhibition hours)
- Evaluation of immuno-therapeutic efficacy in biologically relevant 3D tumor microtissue models
- InSphero’s oncology platform for accelerating drug discovery and development

For more information about InSphero 3D InSight™ solutions for oncology, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
Chief Technology Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

27.03.2017 - InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing

InSphero 3D Liver Microtissues Featured at Annual SOT Meeting as More Sensitive Model for DILI and Mechanistic Toxicity Testing 

Customer and company presentations highlight InSphero 3D InSight™ Liver Microtissues as superior toxicology screening tool. PDF Version

Schlieren, Switzerland - March 27, 2017 – InSphero 3D InSight™ Human Liver Microtissues were identified as a more sensitive, highly specific in vitro model for predicting drug induced liver injury (DILI) and investigating mechanisms of drug toxicity in a series of presentations at the Society of Toxicology’s 56th Annual Meeting (SOT), held in Baltimore, Maryland, March 12-16. InSphero produces 3D liver microtissues using its patent-pending 3D Select™ Process, which yields standardized 3D models that are pre-validated and certified for use in industry-scale in vitro safety and efficacy testing applications.

During the SOT 3D Cell Platforms to Advance Toxicology Sciences workshop, Dr. William Proctor, Head of Investigative Toxicology at Genentech, presented data from an intensive validation study conducted by Genentech and AstraZeneca. The study revealed InSphero Human Liver Microtissues provide twice the sensitivity as traditional primary human hepatocyte (PHH) assays in predicting toxicity of clinically known DILI drugs. Dr. Proctor cited a specific case study in which a blinded compound had shown elevated liver enzymes in Phase I clinical trials in patients. The compound had escaped detection by traditional in vitro screens, but was detected by InSphero 3D InSight™ microtissues at concentrations that reflected clinically relevant dosing levels. Dr. Proctor indicated the model has been instituted in the Genentech group as a secondary (Tier 2) DILI screen.

Commenting on the presentation, InSphero Chief Executive Officer and Co-founder Dr. Jan Lichtenberg, says, ”This study provides convincing evidence that InSphero liver microtissues deliver higher sensitivity without sacrificing specificity. Having two of the world’s leading pharmaceutical companies produce this collaborative, thorough validation further confirms that our 3D models not only reflect in vivo biology, but also deliver the reproducibility and scalability required to meet the early stage screening demands of large pharma. Our assay-ready 3D InSight™ models offer a cost-effective, turn-key solution that gives toxicologists greater confidence when characterizing risk in lead compound sets.”

Additional SOT presentations highlighted the InSphero suite of human and animal-derived liver microtissues for investigative toxicology applications. A novel assay for detecting mitochondrial toxicity was described in collaborative work with Agilent Technologies. Using the Seahorse XFe96 Analyzer to monitor mitochondrial respiration, InSphero 3D InSight™ Human Liver Microtissues displayed a 6-fold increase in spare respiratory capacity compared to 2D PHH, thus providing a significantly larger assay window for detection and classification of mitochondrial liabilities. Oral and poster presentations described the advantages of InSphero rat, monkey, and dog liver microtissues for cross-species analysis of DILI and in vitro mechanistic toxicity studies to reduce the need for costly and ethically charged animal studies.

For more information about InSphero 3D InSight™ Human Liver Microtissues and 3D InSight™ Testing Services, visit www.insphero.com.

 

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer, Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with several national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero Liver Microtissue

InSphero 3D InSight™ Human Liver Microtissues provide greater confidence to pharmaceutical drug discovery and development groups in their efforts to predict drug-induced liver injury in vitro prior to testing in animals or patients.

16.03.2017 - InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

InSphero Launches 3D InSight™ Monkey Liver Microtissues at Annual Society of Toxicology Meeting

3D liver microtissues comprised of cynomolgus hepatocytes provide physiologically relevant in vitro model for investigating species-specific liver toxicity. PDF Version

Schlieren, Switzerland - March 16, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, today announced the launch of 3D InSight™ Monkey Liver Microtissues, further expanding the company’s suite of organotypic 3D liver models for in vitro safety and efficacy testing. Data describing the model’s characterization and application as an alternative to drug testing in animals was presented on Wednesday at the Society of Toxicology’s 56th Annual Meeting and ToxExpo in Baltimore, Maryland.

Drug-induced liver injury (DILI) remains one of the most common causes of late-stage failure in drug development and post-market drug withdrawal. Testing in non-human primates is often required to assess toxicity and potential liver-related side-effects prior to Phase I clinical trials in human patients. 3D InSight™ Monkey Liver Microtissues are a 3D spheroid liver model comprised of primary cynomolgus hepatocytes that serve as an in vitro alternative to in vivo animal tests, enabling testing species-specific effects of a drug on liver function and toxicity in preclinical studies. Viable for more than 28 days in culture, Monkey Liver Microtissues allow long-term drug exposure for predicting DILI and identifying potential mechanisms of toxicity.

InSphero Chief Scientific Officer Dr. Patrick Guye says, “Our 3D monkey liver model addresses the growing trend to reduce or replace the use of animal models in safety testing with more biologically relevant in vitro cell based models. When studies in non-human primates are still required, pre-testing in vitro can help safety and investigative toxicology groups to more effectively plan and minimize the use of costly and ethically charged animal testing. When combined with our human, rat, and dog liver models, our 3D monkey liver microtissues provide toxicologists a more complete toolbox of highly predictive human and animal-derived liver models for in vitro safety testing”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Patrick Guye
Chief Scientific Officer
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

 

Image

InSphero monkey liver microtissue histology

InSphero 3D InSight™ Monkey Liver Microtissues serve as an in vitro alternative to pre-clinical animal testing for assessment of drug effects on liver function and toxicity. 

02.02.2017 - InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

InSphero to Introduce GravityTRAP™ 384 Microtissue Platform at SLAS2017

Global leader in 3D cell culture technology to deliver standardized 3D models in new high-throughput, high-content-imaging-optimized format. PDF Version

Schlieren, Switzerland - February 2, 2017 – InSphero AG, the leading supplier of advanced, yet easy-to-use 3D cell culture-based solutions for drug discovery and development, will debut the GravityTRAP™ 384 Microtissue Platform at the Society for Laboratory Automation and Screening (SLAS) 2017 Conference, February 4-8, in Washington, D.C.

Engineered specifically for 3D microtissue culture, the GravityTRAP™ 384 platform includes two features that differentiate it from existing 384-well plates: distinct microtissue culture and media chambers separated by a tapered SureXchange™ pipetting ledge, providing safe medium aspiration and exchange without accidental loss of microtissues; and a continuous flat-bottomed glass base plate combined with a black-walled body, ensuring superior confocal and high content imaging optics while reducing fluorescent cross-talk between wells. The platform conforms to Society for Biomolecular Screening (SBS) standards and is compatible with state-of-the-art high content imaging and automated liquid handling systems.

“More and more, industry is looking to leverage 3D models that better reflect in vivo biology at earlier stages in drug discovery and development, such as target validation and efficacy screens for potency and selectivity,” said Dr. Jan Lichtenberg, InSphero Chief Executive Officer and Co-founder. “However, the current generation of 384-well plates can cause production inconsistencies, complicate handling steps, and decrease the quality and reproducibility of data obtained. These are all critical factors that impact R&D groups overseeing high-throughput screening (HTS) workflows. The GravityTRAP™ 384 Microtissue Platform addresses these issues, providing a plug-and-play solution for HTS. Our customers will receive 384 of our fully qualified, assay-ready 3D InSight™ Microtissues in a plate that is designed for high-content optics and eliminates accidental loss of microtissues during medium exchange steps.”

InSphero will begin delivering microtissues in the GravityTRAP™ 384 format throughout the year, starting with human liver microtissues for early stage drug-induced liver injury (DILI) screening, and multicellular tumor spheroid (MCTS) co-culture models that recreate complex tumor microenvironments for cancer drug screening. In addition to providing assay-ready models in 96- and 384-well formats, Dr. Lichtenberg said that InSphero will offer contract model development services to screening groups that need custom microtissues for specific 384-well projects. “We can assist research teams by doing the 3D model development for them. Our scientific staff is highly experienced in evaluating which cell types readily form microtissues, and they can efficiently create simple, monoculture 3D models, for example from modified tumor cell lines, as well as more complex co-culture models. Our goal is to not only relieve the microtissue and assay development burden, but also long-term sourcing, production and QC costs.”

For more information about InSphero, visit www.insphero.com.

 

InSphero contacts

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, and tumors. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 GravityTrap 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform enables reproducible production, culture, and high-content imaging of InSphero 3D microtissues in a high-throughput compatible format.

 

GravityTRAP 384 Microtissue Platform

Image caption:

The GravityTRAP™ 384 Microtissue Platform contains distinct microtissue culture and media chambers, separated by a unique SureXchange™ pipetting ledge that prevents accidental microtissue loss during aspiration and medium exchange.

 

 

03.11.2016 - InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

InSphero Scientist Receives 3Rs Award for Microtissue-based Body on a Chip System

Dr. Olivier Frey honored by IQ Consortium and AAALAC International for work on microphysiological system to reduce animal-based drug testing. PDF Version

Schlieren, Switzerland - November 3, 2016 – Dr. Olivier Frey of InSphero AG has received the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe, recognizing his pioneering work to integrate advanced 3D microtissue models into microphysiological systems (MPS) for in vitro drug testing. The award was presented to Dr. Frey at the AAALAC International Luncheon, held Wednesday, November 2 in conjunction with the American Association for Laboratory Animal Science (AALAS) 67th National Meeting in Charlotte, North Carolina. 

The Global 3Rs Awards recognize significant innovative contributions toward the advancement of ethical science through the 3Rs of animal research: refinement, replacement, or reduction of animal use. The award selection committee acknowledged Frey’s work to advance MPS technology by interconnecting 3D microtissues derived from human tissues such as liver, heart, endocrine pancreas, or tumor using microfluidic channels to mimic a so-called “Body on a Chip” or BoC. Such systems serve as complex in vitro models used to assess the efficacy or toxicity of a drug in a multi-organ, animal-free system. Frey headed the research, conducted at the ETH Zurich and in collaboration with partners including InSphero, as part of the European Commission EU Body on a Chip (BoC) Project. The award specifically referenced work published in July of 2015 in the Journal of Biotechnology entitled “3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis,” one of several peer-reviewed publications resulting from the project since 2014.

Dr. Frey, who recently joined InSphero to serve as Microphysiological Systems Product Manager, stated “It is a tremendous honor to receive the 3Rs Award on behalf of all of the scientists who have collaborated on the project since its inception four years ago. As an innovator in the field of 3D cell culture, InSphero was a strong commercial partner and helped keep our work focused on developing a scalable, flexible technology.”

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented, “We are delighted to have a proven leader in microphysiological systems such as Olivier join the InSphero team. His expertise and familiarity with our advanced 3D tissue models will help us accelerate commercialization of the technology, focusing on pharmaceutical and chemical industry applications that reduce both drug development costs and the need for animal testing.”

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
Chief Executive Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 Frey InSphero Portrait web

Dr. Olivier Frey, recipient of the 2016 IQ Consortium and AAALAC International Global 3Rs Award for Europe. Frey currently serves as Microphysiological Systems Product Manager at Schlieren, Switzerland based InSphero AG.

20.10.2016 - 3D Cell Culture Experts Assemble for Inaugural New Frontiers in 3D Conference

3D Cell Culture Experts Assemble for Inaugural New Frontiers in 3D Conference

Event draws over 100 leading government, industry, and academic leaders to further translational applications of 3D tissue models. PDF Version

Schlieren, Switzerland - October 20, 2016 – Experts in next-generation 3D cell culture gathered at the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies Conference, held Thursday, October 13 at Johns Hopkins University in Baltimore, MD. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences (NCATS), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corporation, the first annual conference brought together thought leaders from major disciplines to discuss application of 3D tissue models to improve in vitro assays used for drug discovery and toxicity testing.

Michael Gottesman, MD, Chief of the Laboratory of Cell Biology at the National Cancer Institute and Deputy Director for Intramural Research, National Institutes of Health, and Thomas Hartung, MD, PhD of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT, delivered keynote presentations at the one-day event. Themed sessions featured presentations from some of the world’s leading pharmaceutical, regulatory, and academic research groups working with 3D model systems, including Novartis, the Hubrecht Institute, Merck, the National Institute of Environmental Health Sciences (NIEHS), Pfizer, The Massachusetts Institute of Technology (MIT), University of Innsbruck, and the Russian Academy of Sciences.

Dr. Gottesman, whose research interests include mechanisms by which cancers become resistant to chemotherapy, reinforced in his keynote address that traditional monolayer cell culture models used to study tumor chemoresistance have proven to be woefully inadequate. Gottesman noted, “It should come as no surprise that the world of cell culture is not flat. The meeting was an opportunity to learn about some of the new and exciting advances in 3D cell culture and appreciate the importance of this new technology in studying normal and abnormal cell behavior.”

Jens Kelm, PhD, InSphero Chief Technology Officer and New Frontiers Scientific Advisory Board member, said, “The presentations at the conference underscored how much 3D cell-based assays are becoming a part of the daily operations in drug discovery and drug safety testing to better classify compounds using more predictive models -- the key being robust, uniform, automation-friendly, and easy to use 3D cell models.”

The international New Frontiers in 3D conference will be hosted in 2017 at a European site to be determined, with plans to return to the US in 2018.

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
Chief Technology Officer and Co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of organotypic 3D cell culture models. The company’s patented technologies include the 3D Select™ Process (pending) and scaffold-free 3D cell culture plates that enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain, and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictive power at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and have gained validation in the world’s largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and and LinkedIn, and visit www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

 NewFrontiersAttendees

InSphero 3D InSight Microtissues

press release oct

21.09.2016 - InSphero, US Congressional Leaders Discuss Technologies to Reduce Animal Research

InSphero, US Congressional Leaders Discuss Technologies to Reduce Animal Research

US legislators and InSphero experts discuss benefits of human-derived 3D microtissues for more efficient drug development and less animal testing.

Schlieren, Switzerland - Sept 21, 2016 – InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, met with members of the United States House of Representatives last Thursday to discuss advances in in vitro research technology that can help reduce the use of animals in research. The High-Tech Health Research Expo, organized by Pennsylvania Representative Tom Marino (PA-10), gave InSphero and other life science companies the opportunity to present their technologies to Congressional leaders working to reduce the use of animal testing in the United States. PDF file

InSphero’s flagship products, 3D InSight® Human Liver Microtissues and Human Islet Microtissues, are produced using cells obtained from human donor tissue, which is broken down and reassembled into 3D microtissues using InSphero 3D Select™ Technology. Microtissues are delivered to researchers in a 96-well plate, one microtissue per well, allowing the simultaneous testing of multiple drugs on a standardized, human-derived tissue. Compared to the same cells grown in 2D, 3D microtissues more accurately reflect the native biology of in vivo human tissue, and can be cultured for over four weeks, enabling long-term testing of drug exposure over weeks instead of hours.

Dr. Jan Lichtenberg, InSphero CEO and Co-founder, says the use of more in vivo-like, human-derived 3D model systems is already making a positive impact on drug development pipelines in the pharmaceutical industry. Lichtenberg says, “Our 3D models enable researchers to verify a drug’s efficacy and predict potential toxicity and side-effects using more biologically relevant cell based assays. An additional benefit is less dependency on animal models, the use of which is not only ethically charged, but can also add significant cost, delay time to market, and often fail to accurately reflect how humans will respond to a drug.”

Congressman Tom Marino, an advocate for reducing the use of animal testing for research purposes, says the event accomplished its objective of bringing together legislators and technology providers with a common aim. Marino states, “It was a pleasure to host and recognize InSphero as one of the companies who specialize in alternative, non-animal testing methods. The more stringent restrictions on animal testing imposed in Europe helped InSphero to emerge as a leader in the field of human-based tissue models. They have now established roots in the United States, and are a leading solution provider in the global cause toward developing better drugs while using fewer animals.”

InSphero has worked actively with global organizations such as the Center for Alternatives to Animal Testing (CAAT) and the European Society for Alternatives to Animal Testing (EUSAAT) to advance the use of better in vitro models. Along with CAAT, the National Center for Advancing Translational Sciences (NCATS), and Promega Corporation, InSphero has co-organized the New Frontiers in 3D Cell Culture-based Screening Technologies Conference, which will be held October 13, 2016 in Baltimore, MD.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

Images

Contact This email address is being protected from spambots. You need JavaScript enabled to view it. for high resolution images.

nl pic left nl pic rightInSphero representatives meet congresswoman Dina Titus

Photo caption 1 (left)   

InSphero aims to improve in vitro testing by facilitating the development and use of organotypic 3D cell culture models for safety and efficacy testing. Top left image: InSphero’s patented GravityPLUS® Hanging Drop System. Subsequent images (in clockwise order): assay-ready 3D liver, pancreatic islet, tumor, skin, and brain microtissues.

Photo caption 2 (center)

InSphero representatives met with Congressman Tom Marino (PA-10) at the High-Tech Health Research Expo held September 15 in Washington, DC. Pictured left to right: Dr. Randy Strube (InSphero Director of Global Marketing), Congressman Marino, and Dr. Brian Manning (InSphero East Coast Director of Business Development).

Photo caption 3 (right)

InSphero representatives met with Congresswoman Dina Titus (NV-3) at the High-Tech Health Research Expo held September 15 in Washington, DC. Pictured left to right: Dr. Brian Manning (InSphero East Coast Director of Business Development), Dr. Judi Wardwell-Swanson (InSphero East Coast Field Application Scientist), Congresswoman Titus, and Dr. Randy Strube (InSphero Director of Global Marketing).

 

07.09.2016 - InSphero Launches 3D Mitochondrial Toxicity Testing Service

InSphero Launches 3D Mitochondrial Toxicity Testing Service

New contract screening offering combines advanced 3D liver microtissue models and Agilent XFe96 Analyzer to identify mitochondrial liabilities for drug safety testing market.

Schlieren, Switzerland, Sept 7, 2016 – InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has launched a new service, 3D InSight™ Mitochondrial Toxicity Testing, for the identification of mitochondrial liabilities during drug development and safety testing. Data characterizing the mitotoxicity assay was presented Tuesday at EUROTOX 2016, the 52nd Congress of the European Societies of Toxicology.  PDF file

Mitochondrial toxicity is a major adverse mechanism of toxicity for many drugs assigned black box warnings. When cells encounter stress, such as exposure to toxic drugs, they utilize reserve respiration capacities, which are quantified in the assay as spare respiratory capacity (SRC). A decrease in SRC is one of the first detected consequences of mitochondrial impairment, and the assay compares dose-dependent changes in SRC and cellular viability to assess the likelihood a drug will impair mitochondrial function.

The new service combines the organotypic liver functionality and 28-day in vitro lifespan of 3D InSight™ Human Liver Microtissues with with state of the art analysis of mitochondrial respiration using the Agilent XFe96 Analyzer. The long-term metabolic competence of 3D liver microtissues enables flexible drug exposures of up to 14 days, while the XFe96 Analyzer allows assessment of mitochondrial function through sensitive and precise measurement of cellular oxygen consumption rate (OCR) on a single microtissue level.

Dr. Jens M. Kelm, InSphero Chief Technology Officer and Co-founder, says the service capitalizes on the in vivo-like biology of 3D human liver microtissues. Kelm says, “Mitochondrial SRC serves as the cell’s energy safety net, a reserve that helps cells respond to stress. When grown in 3D, primary human liver cells have a 4-times greater SRC than when grown in 2D. Using 3D microtissues in the assay not only enables us to expose primary human liver cells to drugs for up to 14 days, but also to measure the drug’s impact on mitochondria in a model that more accurately reflects the cellular response to stress in vivo. By comparing the cellular viability to the mitochondrial function after drug treatment, we can determine if mitochondrial impairment is more likely the primary mechanism of toxicity, or rather a secondary effect.”

A tutorial featuring the 3D InSight™ Mitochondrial Toxicity Service is scheduled to appear in the September 15th issue of Genetic Engineering and Biotechnology News (GEN). It is the latest addition to InSphero’s suite of 3D InSight™ In Vitro Toxicology Services, utilized by the world’s largest pharmaceutical and chemical companies to evaluate drug safety.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

13.07.2016 - Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Schlieren, Switzerland, July 13, 2016 – Inaugural meeting, organized by InSphero AG, NCATS, CAAT, and Promega Corp., to be held Thursday, October 13, 2016 in Baltimore, MD.  PDF file

Registration and abstract submission for the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies: Towards greater physiological relevance conference open today via the conference website. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corp., the conference will feature keynote presentations by Dr. Michael Gottesman of the NIH’s National Cancer Institute’s Center for Cancer Research, and Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT.

The one-day symposium, to be held Thursday, October 13, 2016 at the Johns Hopkins University Charles Commons in Baltimore, Maryland, will feature sessions on drug discovery and toxicology, with invited presentations from Novartis, the Hubrecht Institute, Merck, and the NIH’s National Institute of Environmental Health Sciences (NIEHS). Additional speakers will be selected from attendee abstracts submitted for podium presentation, with abstracts for consideration due by August 1, 2016. Abstracts for poster presentations will be accepted until August 15, 2016.

Dr. Jens Kelm, Chief Scientific Officer of InSphero AG and member of the New Frontiers Scientific Advisory Board, says the conference fills what has been a clear gap in scientific forums by focusing on a global view of 3D cell culture technologies. “The goal of this new conference is to assemble an international forum of leaders in the field of 3D tissue models. We aim to offer a balanced perspective of state-of-the-art systems, their adoption and implementation in drug discovery and safety testing, and potential regulatory hurdles to consider as 3D models become standardized and more mainstream.” Kelm notes that the New Frontiers Conference plans to alternate between US and European host cities on an annual basis.

To register or receive more details about the conference, visit the New Frontiers in 3D Cell Culture-based Screening Technologies website.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

11.07.2016 - InvitroCue Commences Pancreatic Toxicity Assay Development

Logo

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. This builds on a previous MOU between InSphero and InvitroCue on the in vitro cell-based hepatotoxicity assay. PDF File

InvitroCue has a history of pioneering technology and establishing industry firsts for liver-related testing assays through its partnerships with leading pharmaceutical and biotech companies. As part of InvitroCue’s objective to cater for increasing demand for more innovative products and services it has also introduced disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis, malaria and perfused human liver tissue. The strategic partnership with InSphero demonstrates the company’s ongoing commitment to deliver customer-centric innovation and best-in-class technological solutions.

“We aim to offer a convenient assay solution for our biopharmaceutical customers to accelerate preclinical anti-diabetic drug development and assessment of potential pancreatic toxicities associated with their metabolites,” commented Dr. Steven Fang, Executive Director of InvitroCue.

InSphero CEO and co-founder Dr. Jan Lichtenberg said, “The collaboration allows InvitroCue to leverage our next-generation 3D InSight™ Islet Microtissues as part of their toxicity testing services, and establishes important inroads as we continue to grow our business in the important Asia-Pacific Market.”

 

For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
This email address is being protected from spambots. You need JavaScript enabled to view it.


About InvitroCue

InvitroCue is an Australian-based biotechnology and life science services company. The Company focuses on the commercialisation of its analytics services using cell-based model and imaging based technology. Its cell-based services enable pharmaceutical and cosmetics companies to refine their drug, ingredient, compound or vaccine discovery efforts. Its digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online Web-based portal. It provides products and services in the field of in vitro drug metabolism and pharmacokinetic (DMPK), in vitro toxicology and digital pathology utilizing cell-based models and analytics. It offers image analytics services for liver disease applications. InvitroCue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). InvitroCue has been developed and validated in collaborations with leading pharmaceutical companies and scientific collaborators. InvitroCue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com

16.06.2016 - Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Schlieren, Switzerland, June 16, 2016 – Liver spheroids display longer culture lifetime, liver-like functionality, and increased sensitivity for detection of hepatotoxic drugs.  PDF Version

Research published by the Karolinska Institute and collaborators as part of the European Community Innovative Medicine Initiative project (MIP-DILI) offers further, independent verification of the utility and promise of 3D liver microtissues for studying liver function, liver diseases and long-term drug-induced liver injury (DILI). The research was published last month in Nature Scientific Reports, an open-access journal.

The paper demonstrates the extended in vitro lifetime and organotypic characteristics of primary human hepatocytes (PHH) when cultured in a scaffold-free 3D configuration, displaying viability and liver-like functionality for up to five weeks in culture. Proteomic analysis revealed that inter-individual variability was retained between spheroids generated from different individual hepatocyte donors. The study also used the prolonged in vitro lifespan of 3D cultured hepatocytes to perform chronic exposure testing of known DILI-inducing drugs, and found they could predict toxicity at clinically-relevant doses. In addition, the spheroid model system proofed to be suitable for studying liver diseases such as cholestasis and steatosis.

Commenting on the publication, Dr. Jens M. Kelm, Chief Scientific Officer and co-founder of InSphero AG says the paper, “Reinforces to the scientific community the benefits of 3D liver microtissues for the purpose of safety assessment during drug development. 3D liver models show enhanced culture lifetime in comparison to standard 2D cultured hepatocytes. This allows for long-term, repeat dose exposure studies, and enhances the sensitivity and predictive power of the model.”

InSphero uses its patent-pending 3D Select™ Process to enable industrial-scale production of 3D liver microtissues for in vitro liver research and DILI testing conducted by the world’s largest pharmaceutical and chemical companies. Dr. Kelm notes that InSphero has performed similar proteomic and genomic characterization of its 3D InSight™ Human Liver Microtissues grown over 28 days in culture, results presented at the EuroTox Annual Meeting in 2015. InSphero’s 3D Select™ Process yields liver microtissues with consistent morphology and viability by ensuring only the healthiest cells incorporate into tissues, a critical difference from conventional methods. “Cryopreserved hepatocytes contain large numbers of necrotic and functionally compromised cells. This percentage varies greatly between donor lots and vendors, making it challenging to make uniform microtissues in the numbers needed for industrial-scale testing. Through our 3D Select™ Process, we remove these compromised cells prior to the aggregation step, making microtissue formation more reliable, while improving morphology and viability. This translates to a more robust, mechanistically accurate in vitro model that enables testing standardization across multiple sites, and across the industry as a whole.”

To find out more about 3D InSight™ Human Liver Microtissues, the 3D Select™ Process, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

16.03.2016 - InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

Schlieren, Switzerland, March 16, 2016 – 3D human liver microtissues comprised of pooled hepatocytes from multiple donors offers more genetically diverse model for DILI detection and prediction.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, today announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The newest liver model is being introduced at the Society of Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana. Failure of drugs during late phases of the drug discovery process costs the pharmaceutical industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to accurately distinguish between known hepatotoxicants and structurally-related non-toxic analogs. The new multi-donor microtissues offer the same structural and functional robustness of single-donor microtissues, but provide a more diverse genetic background to help mitigate bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome P450 enzymes.

Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes from 5 male and 5 female donors, multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of cells for microtissue production. This makes them an ideal tool for in vitro DILI detection and prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”

Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with Kupffer cells, enabling detection of immune-mediated toxicity.

To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Images

multi donor modified2 no backgroundmulti donor icon balanced5

10.02.2016 - InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

Schlieren, Switzerland, February 10, 2016 – Latest update of industry manual for development of high-throughput screening calls on scientists from leading 3D cell culture provider for standardized viability, toxicity protocols.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has contributed a chapter in the NIH National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual, which describes best practices for adapting and standardizing high-throughput assays for use with 3D microtissues. The chapter, “In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays,” was co-authored by Dr. Monika Kijanska and Dr. Jens M. Kelm of InSphero, and appears in a 2016 update to the eBook published last week.

Dr. Terry Riss, Global Strategic Marketing Manager, Cell Health at Promega Corporation, and a contributing editor for the Assay Guidance Manual states, “The new chapter by Drs. Kijanska and Kelm provides expert guidance for scientists moving into the realm of using more physiologically relevant 3D cell culture model systems, and fills a long overdue gap in the content of the Assay Guidance Manual.” Dr. Kelm, Chief Scientific Officer and co-founder of InSphero said, “It was an honor to lend our expertise to such a well-recognized and widely accepted reference guide for cell-based assay and screening communities. It’s a great example of open innovation.” The chapter addresses considerations for choosing an appropriate 3D model, provides guidance on selection of reagents and protocol adaptations proven to work in a 3D setting, and gives specific examples of cell viability and toxicity assay results obtained with InSphero 3D InSight™ Human Liver Microtissues and Tumor Microtissues.

Early iterations of the manual were created by staff researchers at Eli Lilly and Company, but content for the Assay Guidance Manual is currently edited by 19 researchers representing 11 institutions, including NCATS and Lilly. The manual provides guidelines for scientists in academic, non-profit, government and industrial research interested in developing assays useful in screening molecules that modulate biological targets, pathways, or cellular phenotypes. Such molecules may serve as candidates for development of novel drugs for diseases such as cancer, diabetes, neurodegenerative disease, and rare genetic disorders.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

01.02.2016 - InSphero Inc. Streamlines 3D Microtissue Business Operations in US

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

Schlieren, Switzerland, February 01, 2016 – US subsidiary of Swiss-based InSphero AG initiates direct product shipments, progresses towards full-scale US bioproduction capabilities. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has begun accepting orders and processing all financial transactions with customers in North America through its US subsidiary InSphero Inc. The February 1 transition immediately streamlines access to InSphero products and services for US-based customers, and positions the company to initiate operations in its recently completed US bioproduction laboratory in Brunswick, Maine.

Stewart Hunt, General Manager of InSphero Inc., states the transition, “Will dramatically simplify order fulfillment for customers in our largest market by allowing them to order directly from a US source. This eliminates customs processing, additional handling fees, as well as potential delays encountered by those currently using shipment brokers to manage direct international purchases.

The transition accompanies another milestone for InSphero Inc., which has assembled an expert team of 11 US-based employees over the past year. Says Hunt, “We’ve moved quickly, adding key scientific staff to lead the laboratory build-out, technology transfer, and initiate product manufacturing in our state-of-the-art Brunswick facility. Concurrently we have established an experienced team of sales managers, field application scientists, marketing, and product management professionals to provide responsive education and support to our North American customers.”

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stewart Hunt
General Manager, InSphero Inc
Phone +1 800-779-7558 ext. 101
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

25.01.2016 - InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

Schlieren, Switzerland, January 25, 2016 – Study describes high-throughput compatible screening assay using 3D tumor microtissue models to classify efficacy, toxicity, and mechanism of action for compounds in NIH Oncology Library. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologietransfer GmbH, at today’s annual meeting of the Society for Laboratory Automation and Screening (SLAS) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens M. Kelm during Monday afternoon’s Assay Development & Screening poster session.

InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating highly biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than traditional 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines with stromal fibroblasts were generated using InSphero’s patented hanging drop technology. Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration confirmed more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues than to the same cells grown in monolayer. Furthermore, the screen identified three compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking heterogeneous tumor microenvironments when conducting such high-throughput in vitro screens. Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens.

“Here we’ve established a multi-parametric phenotypic screening method that not only factors in tumor size and cell viability, but also discriminates between anti-tumor and non-specific toxic effects of compounds. Using these results, we can determine a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.” In addition to Dr. Kelm’s poster presentation, InSphero microtissues and high-throughput screening and imaging concepts will be featured during several events at SLAS2016, including two exhibitor tutorials and other collaborative posters.

For more information about NCATS, visit www.ncats.nih.gov.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Dr. Jens M. Kelm
Chief Scientific Officer and Co-founder
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

23.10.2015 - InSphero’s CEO Jan Lichtenberg wins Entrepreneur Of The Year™ 2015

InSphero's CEO Jan Lichtenberg wins Entrepreneur of the YearTM 2015

Schlieren, Switzerland, Oct 23, 2015 – Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG received the Ernst & Young Entrepreneur of the YearTM 2015 award in the category "Emerging Entrepreneur". PDF Version

Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG has been awarded the Swiss EY Entrepreneur of the YearTM 2015 award for his leadership in building the Schlieren-based 3D cell culture company into a world-leading technology provider that is helping to revolutionize drug development and chemical safety testing.

pic Jan for PR

Watch EY portrait video 

Winners in four categories: Service/Trade, Industry/High-Tech/Life Sciences, Emerging Entrepreneur and Family Business were selected from 15 finalists by an independent jury, and announced this past Saturday. The four winners stood apart for their company achievement, leadership strenght and convincing promotion of their company through professional and social engagement.

Since 1998 EY has tracked successful entrepreneurs in all sectors, branches, regions and markets within Switzerland. They're all courageous, innovative, willing to take risks, reliable, engaging and strong; they are the backbone of the Swiss national economy. EY Entrepreneur of the YearTM is the only entrepreneurial award program with a global dimension, with 60 participating countries around the world honoring entrepreneurial excellence.

A jury will elect the World Entrepreneur of the YearTM from the pool of national winners at the spring 2016 ceremony to be hosted in Monte Carlo.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

21.10.2015 - InSphero Receives € 750K Funding from EU-ToxRisk Consortium

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

 

Schlieren, Switzerland, Oct 21, 2015 – In a large (€ 30 MM) H2020-supported collaborative project, leading 3D cell culture technology provider joins consortium to jointly foster more efficient, animal-free chemical safety assessment.  PDF Version

InSphero AG, the leading provider of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has been awarded € 750K in funding over six years as part of the € 30 MM EU-ToxRisk collaborative project funded by Horizon 2020.

An international consortium of 39 partner organisations will be funded by the European Commission to work on the integration of new concepts for regulatory chemical safety assessment. These new concepts involve cutting-edge human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular mechanistic understanding of toxicity into safety testing strategies. The ultimate goal is to deliver reliable, animal-free hazard and risk assessment of chemicals

Coordinated by Bob van de Water, Professor of Toxicology at the University Leiden (The Netherlands), EU-ToxRisk has the ambition to become the flagship in Europe for animal-free chemical safety assessment. The project will integrate advancements in cell biology, omics technologies, systems biology and computational modelling to define the complex chains of events that link chemical exposure to toxic outcome. The consortium will provide proof of concept for a new mechanism-based chemical safety testing strategy with a focus on repeated-dose systemic toxicity as well as developmental and reproductive toxicity. Importantly, novel mechanism-based test methods will be integrated in fit-for-purpose testing batteries that are in line with the regulatory framework and will meet industrial implementation. EU-ToxRisk will develop new ab initio quantitative risk assessment approaches based on understanding of so-called “Adverse Outcome Pathways” incorporating all mechanistic toxicity data available in the public domain. It will also achieve a rapid improvement of so-called “read across” approaches as the most important data-gap filling and hence animal-saving alternative method at present. Thus, the project strives towards faster safety evaluation of the many chemicals used by industry and the society.

InSphero CSO and co-founder Dr. Jens Kelm says the award, “serves as a key indicator of the value being placed on advanced 3D models in the project, as they provide greater longevity to enable repeat-dose testing in vitro, and improved biological relevance and mechanistic accuracy relative to traditional 2D cell culture models.   Much of the in silico and predictive modelling algorithms are based upon large amounts of data accumulated using 2D models, so 3D microtissues stand to be a valuable resource in helping to update and refine that data to increase its predictive value.  We are excited to lend our expertise in developing and producing a diverse range of organotypic microtissues, implementing state-of-the-art 3D optimized assays, and integrating microtissues into Body-on-a-Chip systems to advance the aims of the consortium.” 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

15.10.2015 - InSphero Adds Chief Financial Officer to Senior Management Team

InSphero Adds Chief Financial Officer to Senior Management Team

Schlieren, Switzerland, Oct 15, 2015 – Oliver Krähenbühl brings 25 years of finance experience in the technology industry, strengthens senior team at global leader in 3D cell culture. PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has appointed Oliver Krähenbühl to serve as Chief Financial Officer. Mr. Krähenbühl joins the InSphero senior management team having previously held CFO positions at HF Global Inc. New York, Canon, and JobCloud AG, the leading Swiss online professional recruiting company.

InSphero CEO and co-founder Dr. Jan Lichtenberg states the company “stands to benefit immediately from Oliver’s decades of experience, including 15 years at an executive management level and significant cross-Atlantic know-how. In Oliver we have gained a proven expert to guide us financially through our next phase of global trade and operational expansion, particularly following the recent securing of our Series C financing round. We are excited to have him as a member of our team.”

A native of Switzerland and a Swiss Certified Expert in International Accounting and Controlling, Mr. Krähenbühl earned his MBA at the University of Chicago - Booth School of Business. Prior to his previously held CFO positions, he served in various financial, systems integration and project management capacities at Hewlett Packard.

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

13.10.2015 - InSphero Launches 14 Day Hepatotoxicity Testing Service

InSphero Launches 14 Day Hepatotoxicity Testing Service

Schlieren, Switzerland, Oct 13, 2015 – Monthly contract screening service simplifies long-term, repeat-dose testing of drugs in 3D human liver microtissues for global pharmaceutical market. PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in their patent-pending 3D InSight™ Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3D liver microtissues by initiating regular screening runs on the first Tuesday of each month at a cost of $990 per compound.

The newest addition to the company’s growing portfolio of 3D InSight™ Services takes advantage of the more liver-like functionality and greater than 4 week in vitro lifespan of primary liver cells (hepatocytes and Kupffer cells) when co-cultured as 3D spheroids, allowing repeated dosing of compounds over the two week testing protocol. Such testing is unique to 3D cultures, as the same cells grown in 2D (monolayer) culture live only a matter of days, allowing only limited assessment of drug toxicities. The service quantifies total cellular adenosine triphosphate (ATP) as a measurement of cell viability, an assay routinely used to assess drug induced liver injury (DILI). Results for test compounds and defined control compounds are returned to the customer three weeks after initial dosing.

Since its commercial launch in 2010, InSphero has seen the rapid adoption of its 3D InSight™ Microtissues and Services by leading pharmaceutical, chemical and cosmetics companies. More recently, large pharma organizations have completed validation studies and begun converting from conventional assays to InSphero’s 3D microtissues.

Dr. Johannes Haugstetter, Director of Services for InSphero, says exposing cells to drugs over 14 days can reveal toxicity at lower doses than seen when only treated for a matter of hours or days, as in 2D hepatocyte assays. “Long-term exposure in 3D models more accurately predicts potential drug toxicity by mimicking native liver tissue and the repeated exposure to drugs that would be experienced by a patient repeatedly taking the drug. 14 Day Hepatotoxicity Testing provides more reliable evidence of a drug’s safety or potential toxicity, and does so at a fraction of the cost of animal models, which may not accurately reflect the response in humans. Growing acceptance of our liver microtissues as a more predictive and mechanistically relevant model necessitated the adoption of a convenient format for routine, long-term testing of compounds that emerge from primary screens.”

The 14 Day Hepatotoxicity Testing Service complements an array of InSphero standard and custom service offerings, including endpoints to determine functional and mechanistic drug toxicity in 3D microtissues derived from liver, pancreas, heart, brain and skin.

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Johannes Haugstetter
Director of Services
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

29.09.2015 - InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

Schlieren, Switzerland, September 29, 2015 – Patent establishes protection of InSphero GravityPLUSTM technology in all major global markets, key milestone for leading provider of 3D cell culture platforms, microtissues and services.  PDF Version

The United States Patent and Trademark Office (USPTO) officially granted InSphero AG full protection of its GravityPLUSTM hanging drop technology. InSphero, the world's leading developer of easy-to use solutions for organotypic 3D cell culture models and body-on-a-chip systems, now holds hanging drop patents in the world's major pharmaceutical and biotechnology markets, including the United States, Europe, China, Japan, and Singapore. The core patent WO2010031194 describes multi-well plates which allow the generation of hanging drops for 3D cel culture, using convenient top loading of the cell suspension.

InSphero commercialized the hanging drop technology as the GravityPLUS™ Hanging Drop System in 2010.  The system includes the GravityPLUS™ plate used for production of 3D spheroids in hanging drops, and also the companion GravityTRAP™ culture and assay plate, to which 3D microtissues are transferred for long-term culture and drug testing. 

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the favorable decision has been a long time coming for InSphero.  “We are excited the USPTO has recognized the originality of our design, and granted protection of the investment we have made into the creation of new technology.  This protection allows us to operate unhindered in the US market, gives our customers the added confidence to invest in InSphero technology as their platform of choice for 3D cell culture, and provides the grounds necessary to defend against industry competitors attempting to imitate our technology.”

Granting of the patent on September 8 followed InSphero’s recent completion of a Series C financing round, and August announcement naming PerkinElmer as the exclusive global distributor of InSphero hanging drop and ultra-low attachment (ULA) plates for 3D cell culture. 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

05.08.2015 - InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms

InSphero Expands Global Availability of its Patented 3D Cell Culture
Platforms

Schlieren, Switzerland, August 5, 2015 – PerkinElmer named as exclusive distributor of InSphero state-of-the-art 3D culture
technology. 
PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, announced today that its patented GravityPLUS™ Hanging Drop System and new GravityTRAP™ Ultra-Low Attachment (ULA) Plates are now available for purchase exclusively through PerkinElmer.

InSphero will now broaden global access to its 3D cell culture plates, while simplifying ordering and delivery logistics for a worldwide customer base. Working with PerkinElmer, InSphero will be better able to meet increasing demand for reliable methods to grow cells as more biologically relevant 3D spheroids. Furthermore, this agreement will provide additional capabilities to PerkinElmer’s extensive portfolio of consumables, assays, and imaging systems, which the two companies have used to develop novel assays for drug discovery, safety, and efficacy testing.

“The agreement immediately accelerates our ability to efficiently supply and deliver InSphero plate technologies internationally, and also forges a strategic relationship for the continued development of next-generation 3D cell culture platforms, as well as 3D-optimized imaging and cell-based assay protocols,” says Dr. Jan Lichtenberg, CEO and co-founder of InSphero.

Lichtenberg notes that the relationship between the two companies has already yielded novel, high content imaging applications for assessing compound toxicity in liver microtissues, and enabled users to perform RNA interference screens to sensitize tumor spheroids to radiation in research applications.

“Our customers will benefit from PerkinElmer's global reach and technical expertise in experimental workflows when ordering and using InSphero plates. Our reliable, automation-compatible 3D cell culture platforms complement PerkinElmer’s assays and high-content imaging systems,” said Dr. Lichtenberg.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

08.07.2015 - InSphero AG Secures CHF 20 Million Series C Financing

InSphero AG Secures CHF 20 Million Series C Financing

Schlieren, Switzerland, July 8, 2015 – Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.  PDF Version

InSphero AG, the world's leading developer of easy-to-use solutions for organotypic 3D cell culture models and body-on-a-chip systems, has secured CHF 20 million in financing from the family investment office of a globally active entrepreneur represented through HP WILD HOLDING AG based in Zug, Switzerland. InSphero is using the Series C financing round to rapidly expand its global footprint, broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing, and develop new products and applications based on its proven technology.

Since its commercial launch in 2010, the company has experienced strong year-over-year sales growth marked by the rapid adoption of its 3D InSight™ microtissues and services by leading pharmaceutical, chemical and cosmetics companies. Since last year, large pharma organizations have begun converting from conventional assays to InSphero's 3D microtissues.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the investment round enables InSphero to leverage the successful customer implementations, robust validation data, and growing scientific evidence to become the gold standard in the field of 3D cell-based assays.

"This investment is an affirmation of InSphero's valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process," said Lichtenberg. "The family office behind HP WILD HOLDING AG brings to InSphero long-term perspective as well as decades of experience building global brands and driving operational excellence. Their financial commitment is also strengthened by an established international network that will help us better serve growing global demand for microtissues and services, particularly in North America and Asia."

The proceeds of the financing round will be invested to expand InSphero's North American scientific staff and operations into a state-of-the art bio-production facility; increase the variety of model systems available to customers across different industries; and to develop new products including InSphero's Body-on-a-Chip technology and personalized-medicine kits to maturity.

InSphero's pipeline includes 3D liver, skin, heart, brain and tumor models developed for toxicity testing and disease modeling, as well as next-generation 3D cell culture platforms.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

07.05.2015 - InSphero Launches Enhanced Ultra-low Attachment Spheroid Plate for Scaffold-free 3D Cell Culture

InSphero Launches Enhanced Ultra-low Attachment Plate
for Scaffold-free 3D Cell Culture

Schlieren, Switzerland, May 7, 2015 – GravityTRAP™ ULA Plate design simplifies medium exchange and improves imaging during spheroid production and culture.  PDF Version

InSphero AG, the leading provider of scaffold-free 3D microtissues, cell culture technology, and 3D-focused contract research testing, announced today the release of their new GravityTRAP™ Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format expands InSphero's portfolio of tissue culture platforms for scaffold-free 3D cell culture, offering a low-cost, enhanced ULA plate ideal for production of 3D tumor microtissues derived from tumor cell lines, or to screen for the propensity of cells to form spheroids in a low-attachment environment.

The GravityTRAP™ ULA Plate includes wells specially coated to prevent attachment and monolayer growth of cells, and provides significant advantages over existing ultra-low attachment spheroid plates, including simplified medium exchange and improved imaging. Each well incorporates a SureExchange™ tapered ledge design that simplifies the process of changing growth medium during long term culture or compound dosing, and protects spheroids from disruption or accidental aspiration. The narrow (1 mm diameter) growth chamber in each well features a flat bottom, eliminating focal distortion that can
complicate imaging in round-bottom ULA plates.  The narrow chamber provides the necessary concentration of cells required to promote formation of a single microtissue per well, while making it easier to locate and image even small (<100 μm diameter) spheroids.

Users of InSphero's GravityPLUS™ hanging drop system will likely be familiar with the GravityTRAP™ ULA Plate, as it already serves as the long-term culture and assay plate provided with the patented hanging drop system. Dr. Simon Messner, Product Manager at InSphero, notes offering the GravityTRAP™ ULA Plate as a stand-alone platform offers a cost-effective option for researchers looking to move their cell culture into 3D, or who may currently be experiencing the limitations of existing ultra-low attachment plates. "We recommend the GravityTRAP™ ULA Plate as a first-line option for testing or confirming the spheroid-forming capacity of cells, particularly tumor cell lines, as they may not require the improved oxygenation and complete elimination of cell-surface interaction afforded by the hanging drop technique to form spheroids. The GravityPLUS™ system is still the platform of choice for production of more  complex 3D microtissues, such as those derived from patient- or animal-derived (primary) cells or multi-cell type co-culture models."

InSphero CEO and co-founder Dr. Jan Lichtenberg states the benefits of the new platform extend beyond its design features. "With the GravityTRAP™ ULA Plate and GravityPLUS™ system, researchers have not only two reliable scaffold-free platforms, but also the confidence of purchasing their technology from a company with extensive 3D cell culture experience and know-how. This includes specially formulated growth medium to promote spheroid formation or long-term culture maintenance, 3D-optimized protocols to help extract the most data, and custom model development and compound screening through our 3D InSight™ Services."

To find out more about the benefits of scaffold-free 3D cell culture, or to learn more about InSphero visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is the world's leading supplier of organotypic, biologically relevant in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top 15 global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup and ACES Award Winner for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

17.03.2015 - InSphero Publication Honored for Potential to Reduce Use of Research Animals

InSphero Publication Honored for Potential to Reduce Use of Research Animals

Schlieren, Switzerland, March 17, 2015 – Nature Communications paper co-authored with ETH Zurich wins "highly commended" honor from NC3Rs.  PDF Version

Research conducted by InSphero AG, the world’s leading supplier of 3D microtissues for in vitro safety and efficacy testing, and collaborators at ETH Zurich has received the “highly commended” honor from the British National Center for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Dr. Olivier Frey of ETH Zurich, first author on the paper published last June in the journal Nature Communications, accepted the award at the 3Rs Prize ceremony held last week in London.

The paper, entitled “Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis,” reported a novel approach to culturing multi-cellular 3D microtissues in vitro, and for the first time joined hanging drop cell culture with microfluidics. Growing spheroids in hanging drops removes restrictions associated with scaffolds, while microfluidics allow continuous medium and waste exchange, and allowing test substances such as candidate drugs to be dosed into the culture medium. The body-on-a-chip (BoC) system successfully displayed the ability to interconnect spheroids from two different tissue types (liver and tumor) which were able to communicate with each other via metabolite transfer. The principle was demonstrated using bioactivation of the anti-cancer drug Cyclophosphamide by the liver, and subsequent inhibition of tumor spheroid growth.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented,”Multi-tissue in vitro test systems hold promise in the drug development industry as a better means of predicting the safety and efficacy of novel agents, while reducing the dependency on using animals for such studies.” Lichtenberg noted most BoC concepts to date focus on joining individual chambers of cells cultured in 2-dimensional monolayers, which is the current industry standard for most in vitro cell based assays. “Our 3D InSight™ Liver, Islet, and Tumor Microtissues continue to provide striking evidence that 3D cell culture displays a more organotypic, biologically relevant phenotype than 2D. Naturally it follows that interconnecting spheroids would be an ideal approach to recapitulating a multi-organ system, something this research conceives in a scalable and flexible BoC format.”

The collaboration has yielded two additional publications since the award winning Nature Communications paper last June, including recent articles in the Journal of Laboratory Automation and the Journal of Biotechnology.

NC3Rs is a UK-based scientific organization dedicated to replacing, refining and reducing the use of animals in research and testing. The 3Rs Prize is sponsored by GlaxoSmithKline.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

10.03.2015 - Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Schlieren-Zurich, Switzerland, March 10, 2015 – InSphero, Biognosys paper reveals relevant proteomic changes in liver at sub-toxic doses.  PDF Version

InSphero AG, a leading supplier of 3D microtissues for in vitro safety and efficacy testing, and Biognosys AG, a leader in next-generation proteomics have teamed up to publish research in Molecular & Cellular Proteomics entitled "Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen treated 3D liver microtissues". The paper represents the latest milestone in characterizing InSphero's 3D microtissues as a superior model system for in vitro toxicity testing. The study was co-authored by researchers from Purdue University and ETH Zurich, and will be presented at the upcoming Society of Toxicology meeting in San Diego, California.

In the study, proteomic changes in acetaminophen (APAP)-treated 3D InSight™ Human Liver Microtissues were quantified with HRM-MS™, a next-generation proteomics technology developed by Biognosys that is based on data-independent acquisition (DIA) performed on new generation mass spectrometric systems. The abundance of 2,830 proteins was quantified over an APAP physiological concentration range with a starting material of 12,000 cells per sample. Proteins from all three phases of drug metabolism were identified as regulated. Moreover, for the first time the exact NAPQI‐cysteine adduct sites were mapped on proteins possibly relevant for the toxicity of APAP.

Dr. Jens M. Kelm, CSO and co-founder of InSphero stated "the combination of our organotypic 3D microtissue model system and the HRM profiling technology proved to be a powerful approach for discovery experiments, revealing novel modes‐of‐action, toxicity upon drug treatment, and new biomarkers. HRM-MS makes yet another useful endpoint available to our customers for extracting high-value information from our microtissues, particularly global proteomic changes in response to drug treatment."

Dr. Kelm noted the enhanced longevity and more native metabolic phenotype of 3D microtissues made them suitable for such long-term, repeat-dose toxicity studies, and importantly, the HRM approach was able to identify and quantify for the first time human protein targets of drug-adducts in sub-toxic APAP concentrations. InSphero's 3D InSight™ Human Liver Microtissues are established using primary human hepatocytes (PHH) and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jens M Kelm, CSO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as a spin-off
from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., www.biognosys.ch

21.01.2015 - 3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

Schlieren, Switzerland, January 21, 2015 – European consortium will use 3D liver tissues to better predict drug-induced liver injury.  PDF Version

Leaders of the European project "Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury" (MIP-DILI) project have reported they will use 3-dimensional (3D) liver spheroids against a panel of other in vitro test systems aimed at developing novel preclinical tests to improve the safety evaluation of drugs likely to cause drug-induced liver toxicity before subsequent evaluation in clinical trials.  Along with its academic and EFPIA partners, the MIP-DILI consortium is funded equally by the EU Innovative Medicines Initiative (IMI) and EFPIA companies, and is in year three of the €32.4 million 5-year program.

In early project work, primary human hepatocytes (PHH), cells isolated from human liver donors, outperformed tumor-derived or other immortalized liver cell lines in terms of metabolic activity but with apparently mixed sensitivity to known DILI-inducing drugs.  InSphero, the leading supplier of 3D cell culture products and services to the  pharmaceutical industry, along with a number of other commercial technology suppliers were invited to participate in the next round of studies, where PHH were grown and assayed in a variety of formats that included static 2D culture, perfusion cultures, and 3D spheroids. Among the participating commercial suppliers contributing to the study, 3D spheroids emerged as the culture platform that most resembled liver-like biology and responded to a number of liver toxins with a certain enhanced sensitivity, which now requires further investigation.

Dr. Phil Hewitt, co-leader of the project's 'Established and novel in vitro cell systems' work package, says "3D spheroids proved to offer more than just superior biological relevance, they also provide the scalability and compatibility necessary to work with commercial assays and automation systems, and can do it at a more reasonable cost than other systems evaluated in the early phase studies.  Liver spheroids will play a key role in the predictive in vitro tests being developed as the project progresses."

The findings were presented last fall at EUROTOX 2014 in Edinburgh, UK, in talks that summarized a thorough two-year evaluation of available liver cell sources and cell culture formats being considered.

InSphero supplies assay-ready 3D microtissues and 3D-focused screening services to the pharmaceutical and cosmetics industry, counting the world's top 15 pharmaceutical companies as their clients.  InSphero's 3D InSight™ Human Liver Microtissues are established using PHH and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.  Growing the cells in 3D results in a long-lived microtissue that more accurately mimics the cell architecture and metabolic phenotype of native liver compared to traditional 2D cultured PHH.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing, phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder, phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it.www.insphero.com

Disclaimer

MIP-DILI is jointly funded by EFPIA and Innovative Medicines Initiative. The press release by no means endorses MIP-DILI or its members in using InSphero products for drug discovery & development. MIP DILI endorses/recognizes the imperative value of comparing the quantitative evaluation of all test systems for drug safety evaluation in line with its primary objective http://www.mip-dili.eu/

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

 

Media Release images

For a high-resolution view click on an image below.

28.05.2014
Pancreatic Microislets for Diabetes

Media release 28.05.2014 - Pancreatic Microislets for Diabetes

11.04.2014
Dainippon Screen Cell3iMager

Media release 11.04.2014 - Dainippon Screen Cell3iMager

11.04.2014
96well Spheroids

Media release 11.04.2014 - 96well Spheroids

11.04.2014
Tumor Spheroid

Media release 20.03.2014 - Tumor Spheroid

 

20.03.2014
3D Tumor Microtissue

Tumor cells grown in 3D spheroids

27.02.2014
GravityPLUS plate

gravity-plus-culture-assay-96-plate

27.02.2014
3D InSight Tumor Microtissue

insphero-tumor-microtissue2

30.01.2014
Rat Liver

inspherp-rat-liver-thumb

28.01.2014
R. Strube

insphero-randy-strube-thumb

 

Media Releases Archive

Company video

company-video-inspheor